Development of a Natural Cannabinoid Product

描述(申请人提供)：大麻(大麻)和一些数量 大麻素及其主要精神活性成分Delta9-THC (Delta9-四氢大麻酚)，显示出治疗疼痛和恶病质的希望 癌症和艾滋病患者。这项研究计划的总体目标是 开发用于医疗用途的天然药用级Delta9-THC产品。 虽然Delta9-THC可以合成，但过程复杂且昂贵。它 我们的假设是天然的Delta9-THC产品可以经济高效地 利用超临界流体和近临界流体w/wo制造 极性助溶剂，如醇(超流体TM)，以及这样的过程 还可以生产其他生物活性大麻素和大麻素混合物 未来的研究和治疗用途。在第一阶段，我们计划建立“最好的” 选择性超流萃取和层析条件的研究 大麻Delta9-THC的纯化(CXP)超流体CXP 将对照传统的有机相工艺对工艺进行评估 资本和运营成本以及对环境的影响。结果是 我们的第一阶段调查将用于执行工程和经济 分析以确定技术、经济和环境可行性 拟议的流程。在第二阶段，我们将扩大和试行这一进程 由分子递送公司生产用于商业化的大麻素， 加利福尼亚州普莱森顿

DESCRIPTION (provided by applicant): Marijuana (Cannabis sativa) and a number of cannabinoids including its primary psychoactive component, delta9-THC (delta9-tetrahydrocannabinol), show promise for treating pain and cachexia in cancer and AIDS patients. The overall goal of this research program is to develop a natural pharmaceutical grade delta9-THC product for medical use. While delta9-THC can be synthesized, the process is complex and expensive. It is our hypothesis that a natural delta9-THC product can be cost-effectively manufactured by utilizing supercritical fluids and near-critical fluids w/wo polar cosolvents such as alcohols (SuperFluids TM), and that such a process could also produce other bioactive cannabinoids and cannabinoid mixtures for future research and therapeutic use. In Phase I, we plan to establish "best" conditions for selective SuperFluids extraction and chromatographic purification (CXP) of delta9-THC from Cannabis sativa. The SuperFluids CXP process will be evaluated against conventional organic phase processes in terms of capital and operating costs as well as environmental impact. The results of our Phase I investigation will be used to perform engineering and economic analysis to determine the technical, economic and environmental feasibility of the proposed process. In Phase II, we will scale-up and pilot the process for producing cannabinoids for commercialization by Molecular Delivery Corporation, Pleasanton, CA.